Evolving Strategies for Leveraging SGLT2 Inhibitor Therapy in Type 2 Diabetes

Get patient-specific guidance on T2D treatment options and insights on managing CVD and CKD risk.
Martin J. Abrahamson, MD, FACP
Zachary T. Bloomgarden, MD, MACE
Anne Peters, MD
Richard E. Pratley, MD
Robert S. Zimmerman, MD

ClinicalThought

SGLT2 inhibitors play important roles in our new person-centric approach for managing T2D. Here’s my take on how SGLT2 inhibitors can be used to mitigate cardiovascular and renal disease, along with how I approach treatment selection in challenging clinical scenarios.

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: November 10, 2020 Expired: November 9, 2021

Downloadable Slideset

Learn about the role of SGLT-2 inhibitors in treating type 2 diabetes.

Anne Peters, MD Released: December 10, 2020

Interactive Decision Support Tool

Access expert recommendations to individualize treatment and minimize CV, HF, and CKD risks for patients T2D

Martin J. Abrahamson, MD, FACP Zachary T. Bloomgarden, MD, MACE Anne Peters, MD Richard E. Pratley, MD Robert S. Zimmerman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 9, 2020 Expired: December 8, 2021

Interactive Virtual Presentation

Hear expert discussion of the role of SGLT-2 inhibitors in treating type 2 diabetes.

Anne Peters, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: December 10, 2020 Expired: December 9, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue